HOME › Research Insight › Zoetis, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Virbac (France), and Eli Lilly and Company (U.S.) Dominate the Global Animal Antibiotics and Antimicrobials Market
Zoetis, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Virbac (France), and Eli Lilly and Company (U.S.) Dominate the Global Animal Antibiotics and Antimicrobials Market
The global animal antibiotics and antimicrobials market is dominated by Zoetis, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Virbac (France), and Eli Lilly and Company (U.S.) which together accounted for ~65.0-70.0% of the global market in 2015.
The leading position of Zoetis, Inc. (U.S.) in this market is majorly attributed to its strong product portfolio, wide geographic presence, and strong distribution and services network across the globe. Moreover, the company has a diversified revenue system, which helps it to sustain its leading position in the market. The company operates in 70 countries and sells products in over 120 countries through its strong distribution network. The company majorly focuses on expanding its manufacturing capacity to meet the growing demand of healthcare products for companion as well as food-producing animals. The company also focuses on R&D activities to develop animal health solutions that meet the customers’ demands. In this regard, in 2015, the company invested USD 364 million in R&D activities for the discovery and development of new chemical and biological entities, as well as for product lifecycle development. In 2015, the company received approximately 200 product approvals, including approvals of new and novel products, lifecycle innovations for current products, new combinations of products, and approvals of portfolio products in new markets. Moreover, the company focuses on direct interaction with its customers, which gives it a competitive advantage over others.
Merck & Co., Inc. (U.S.) held the second-largest share in the animal antibiotics and antimicrobials market in 2015. The company has its R&D facilities in North America, Europe, and Asia-Pacific, and operates through its major subsidiaries based in Canada, Japan, China, the U.K., and UAE. Merck Animal Health offers veterinarians, farmers, pet owners, and government veterinary institutes the widest range of veterinary pharmaceuticals, vaccines, and health management solutions & services. The company leverages its research capabilities and innovative product portfolio to garner a larger share and sustain its leading position in the animal health market. The company invested USD 6,704 million, USD 7,180 million, and USD 7,503 million on research and development activities in 2015, 2014, and 2013, respectively, to develop and formulate innovative human and veterinary pharmaceuticals
Bayer AG (Germany) held third-largest share in the global animal antibiotics and antimicrobials market in 2015, with core competencies in the fields of healthcare, agriculture, and high-technology polymer material sciences. The strong position of the company in this market is primarily attributed to its robust product portfolio and strong geographic footprints. The company has a strong presence in 120 countries across the Americas, Asia, Europe, and Oceania. For the growth of its animal health business, the company focuses on organic strategies, such as the expansion of its R&D activities and the increased use of its existing distribution channels. For instance, in September 2013, the company established the Centre for Innovation and Development (CID) in Auckland, New Zealand to carry out research into the health and wellness of both companion and farm animals.
Industry players adopted the strategy of acquisition and new product launches to achieve growth in the global animal antibiotics and antimicrobials market. For instance, in April 2016, Dechra Pharmaceutical PLC (U.K.) acquired Putney, Inc. (U.S.), a provider of high-quality, bioequivalent, and specialty drugs (generic drugs) for companion animals. To avoid the antibiotic and antimicrobial resistance in animals, companies are investing more to develop animal use specific antibiotics and antimicrobials. In this regard, in 2016, Elanco, animal health division of Eli Lilly and Company launched only animal use antibiotics such as Inteprity, Surmax, and Kavault to maintain health of pigs and poultry birds.
Animal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Fluoroquinolone), Mode of Delivery (Premixes, Oral Powder, Injection), Animal (Food-producing & Companion) - Global Forecast to 2021
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India